Company intelligence / Profile preview

Yangzhou Yiyang Pharmaceutical

Yangzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Yangzhou Yiyang Pharmaceutical is a China-based pharmaceutical company focused on the research, development, and commercialization of innovative small molecule drugs. The company primarily targets metabolic diseases, with a significant emphasis on treatments for type 2 diabetes and hyperuricemia. Their pipeline includes several proprietary candidates currently in clinical development, such as SGLT2 inhibitors and DPP-4 inhibitors. Yangzhou Yiyang aims to provide high-quality, affordable therapeutic options for chronic conditions prevalent in the Chinese market and beyond.

Therapeutic areas: EndocrinologyRheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Yangzhou Yiyang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangzhou Yiyang Pharmaceutical.

Explore the full profile